MYCO-006

MYCO-006 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.^[1][2][3][4] It is a short-acting and fast-onset MDMA analogue.^[3][4] Based on animal studies, it is predicted that MYCO-006 will have a duration of 1 to 2 hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4 times as fast as MDMA.^[4] MYCO-006 is being developed by Mydecine.^[1][2][3][4] As of February 2024, it is in preclinical research.^[1][2] The chemical structure of MYCO-006 does not yet appear to have been disclosed.^[1][2] 5-BZT-MDMA and 6-BZT-MDMA were described in Mydecine's patent for short-acting MDMA analogues.^[5][6][7]